DARE - Daré Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8000
-0.0054 (-0.67%)
At close: 4:00PM EDT

0.8400 +0.04 (5.00%)
After hours: 5:24PM EDT

Stock chart is not supported by your current browser
Previous Close0.8054
Open0.8000
Bid0.7800 x 3100
Ask0.8500 x 800
Day's Range0.8000 - 0.8159
52 Week Range0.6000 - 3.2500
Volume40,955
Avg. Volume361,983
Market Cap13.347M
Beta (3Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire12 hours ago

    Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it has received notification from the American Association of Pharmaceutical Scientists (AAPS) of a Best Abstract Award for the abstract titled, Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model. The abstract was among the top 10% of abstracts highly ranked by AAPS Abstract Screeners.

  • GlobeNewswire2 days ago

    Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced today that William H. Rastetter, Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019. “I believe Daré is poised to deliver on a number of significant milestones over the next 12 to 24 months.  I am stepping off the board for personal reasons and fully support the company and the board changes.  Bill’s wealth of experience and formidable track record of success in biotech will be instrumental in guiding Daré through its next stage of growth, and I look forward to following the company’s developments,” said Roger Hawley. Among his other awards and recognitions, Dr. Rastetter won the Biotechnology Heritage Award in 2018, an award that recognizes individuals who have made significant contributions to the development of biotechnology through discovery, innovation, and public understanding, for his work as co-inventor of Rituxan®, the first monoclonal antibody (MAb) approved by the U.S. FDA for cancer therapy.

  • GlobeNewswire21 days ago

    Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®

    Ovaprene is a self-administered, hormone-free, novel intravaginal ring, similar in size and shape to NuvaRing®.  Ovaprene is designed to achieve contraceptive effectiveness over multiple weeks without the use of hormones and has the potential to be a first-in-category contraceptive, if approved. There currently is no FDA-approved, self-administered contraceptive that can provide month-to-month contraceptive protection without the use of hormones. This unique dual approach of a physical barrier and spermiostatic environment is designed to provide a contraceptive effect consistent with the most effective barrier option, the diaphragm, and commonly used short-acting hormonal options (contraceptive pill, patches and vaginal ring), which provide 88-91% effectiveness in “typical use.”  All other commonly used or soon to be marketed hormone-free contraceptive products are used at, or shortly before, coitus (including condoms, spermicides, multi-purpose gels) and do not achieve “typical use” contraceptive effectiveness comparable to hormonal methods or are not self-administered (long-acting copper IUDs).

  • GlobeNewswirelast month

    Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in normal healthy women. Sildenafil is the active ingredient in a tablet for oral administration marketed under the brand name Viagra®, which is indicated for the treatment of erectile dysfunction (ED) in men. Daré Bioscience, in collaboration with Strategic Science & Technologies, LLC (SST), is developing Sildenafil Cream as a potential treatment for female sexual arousal disorder (FSAD), a condition analogous to ED in men.  Sildenafil Cream is a topically administered formulation of sildenafil designed to increase local blood flow and provide a potential improvement in genital arousal response and overall sexual experience for women.

  • GlobeNewswire2 months ago

    Daré Bioscience to Present at the 2019 BIO International Convention

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 2019 BIO International Convention on Tuesday, June 4, 2019, starting at 11:15 a.m. Eastern Time in Philadelphia, PA. The BIO International Convention brings together the global biotechnology and pharmaceutical industry and is expected to include over 500 education sessions and networking opportunities with 16,000+ attendees from 67 countries. The theme for the 2019 BIO International Convention is “It Starts with One,” to highlight the critical daily contributions that combine to bring new breakthroughs to the world, and the women and men who bring new ideas and perspectives to the forefront.

  • GlobeNewswire2 months ago

    Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “We believe our differentiated product candidate portfolio is well poised to drive value in 2019 and 2020 as we seek to execute against clinical and regulatory milestones, particularly with our Phase 3 and Phase 2 candidates. During the first quarter, we continued enrollment in the postcoital test clinical trial of Ovaprene, our monthly, non-hormonal contraceptive candidate, and we remain on track to report top-line data in the second half of 2019.

  • GlobeNewswire2 months ago

    Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and Translational Research. The goal of the research was to characterize the in vitro release, pharmacokinetics and local tolerability of DARE-FRT1, a novel ethylene-vinyl acetate intravaginal ring (IVR) drug delivery technology delivering progesterone, in drug-naïve ovariectomized female Dorset crossbred sheep. DARE-FRT1 is being developed as an optimized IVR technology capable of delivering bio-identical progesterone hormone for the prevention of preterm birth (PTB), and for pregnancy maintenance and support as part of an assistive reproductive technology (ART) procedure.  DARE-FRT1 is designed to allow for convenient non-invasive, non-oral administration of bio-identical progesterone over a 14-day period.

  • GlobeNewswire2 months ago

    Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast

    SAN DIEGO, May 07, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • GlobeNewswire3 months ago

    Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring designed to provide multiple weeks of contraceptive protection. The presentation entitled, “Contraception 2019: What about LARC, Rings, Gel, even Apps?”, was given by noted physician and women’s health expert Dr. James A. Simon during the Survival Skills for Today’s Gynecologist continuing medical education conference in New York City on Sunday, April 14th.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock

    Daré Bioscience, Inc. (DARE), today announced the pricing of an underwritten public offering of 4,575,000 shares of its common stock at a price of $1.10 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $4.4 million, assuming no exercise of the overallotment option, and approximately $5.1 million assuming the overallotment option is exercised in full. Roth Capital Partners is acting as the sole book-runner for the offering.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it intends to offer shares of its common stock in an underwritten public offering.  Daré expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions.

  • GlobeNewswire3 months ago

    Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel 17β-estradiol and progesterone intravaginal ring in sheep” was published online in the Journal of Pharmaceutical Sciences (JPharmSci®). The goal of the research described in the article was to characterize the release, pharmacokinetics and local tolerability of DARE-HRT1, a potential and novel hormone replacement therapy.  DARE-HRT1, an ethylene-vinyl acetate (EVA) intravaginal ring (IVR) drug delivery technology delivering 17β-estradiol (E2) and progesterone (P), was evaluated in drug-naïve ovariectomized female Dorset crossbred sheep. DARE-HRT1 is being developed as a combination bio-identical estradiol and bio-identical progesterone IVR for hormone replacement therapy (HRT) to treat vasomotor symptoms (VMS), commonly called hot-flashes and associated with menopause, as part of an HRT regimen.

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq

    SAN DIEGO, April 01, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it received notice from The Nasdaq Stock Market.

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast

    SAN DIEGO, April 01, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • GlobeNewswire4 months ago

    World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced that Dr. Robert Langer, co-inventor of Daré‘s novel, segmented intravaginal ring (IVR) drug delivery technology and one of the 10 Institute Professors at the Massachusetts Institute of Technology (MIT) joined the company’s Scientific Advisory Board.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Heating Up On Monday

    Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference

    SAN DIEGO, March 18, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire4 months ago

    Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the publication of clinical findings for vaginally-administered tamoxifen in Clinical and Experimental Obstetrics and Gynecology, a leading international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology. Daré’s product candidate, DARE-VVA1, incorporates tamoxifen in a proprietary formulation designed for vaginal delivery. Daré holds the exclusive worldwide rights to patents issued in the U.S. and Japan covering the use and delivery of DARE-VVA1 for vulvar and vaginal atrophy (VVA) and a U.S. patent covering composition, use and delivery of DARE-VVA1 for VVA.

  • GlobeNewswire4 months ago

    Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851, part of a grant providing up to $1.9 million in the aggregate for Ovaprene® research from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). This second award, an additional $982,851, followed the NIH’s review of an interim data analysis and other results of the first phase of work. The award will be applied to important clinical development efforts supporting Ovaprene, a potential first-in-class hormone-free contraceptive solution.

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference

    SAN DIEGO, March 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire5 months ago

    Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 16th Annual BIO Asia International Conference on Tuesday, March 5, 2019 at 4:15 p.m. Japanese Standard Time in Tokyo, Japan. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.  “Given our focus on identifying development and global commercialization partners for our portfolio of women’s health product candidates, we are pleased to have the opportunity to present and participate in the partnering meetings organized by the conference,” said Sabrina Johnson.

  • GlobeNewswire5 months ago

    Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference

    SAN DIEGO, Feb. 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire6 months ago

    Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré.

  • ACCESSWIRE7 months ago

    New Healthcare Trends Pushing Stocks Higher On Thursday

    CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...

  • GlobeNewswire7 months ago

    Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.